NCR Online Journal

Neurofibromatosis 2 Pipeline Insight 2021 by DelveInsight

 Breaking News
  • No posts were found

Neurofibromatosis 2 Pipeline Insight 2021 by DelveInsight

March 17
14:14 2021
Neurofibromatosis 2 Pipeline Insight 2021 by DelveInsight

Neurofibromatosis 2 Pipeline” report has been recently added to Delveinsight

 

About Neurofibromatosis 2

Neurofibromatosis 2 (NF2) is a rare genetic disorder that is primarily characterized by noncancerous (benign) tumors of the nerves that transmit balance and sound impulses from the inner ears to the brain (bilateral acoustic neuromas/vestibular schwannomas).

 

Download free sample copy of Neurofibromatosis 2 pipeline report- https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight

 

Neurofibromatosis 2 Diagnosis

The diagnosis of NF2 is confirmed by a thorough clinical evaluation and specialized testing (i.e., CT scan, magnetic resonance imaging (MRI), pneumoencephalogram, or arteriogram are very rarely used nowadays). Molecular genetic testing for mutations in the NF2 gene is available for most affected individuals who have a positive family history.

 

Neurofibromatosis 2 Causes

NF2 is caused by a mutation in the NF2 gene. The NF2 gene regulates (encodes for) the production of a protein known as merlin/schwannomin that plays a role in suppressing the development of certain tumors (tumor suppressor). According to investigators, merlin/schwannomin is related to a class of proteins (ezrin-radixin-moesin proteins) that serve to link the internal, supportive system within a cell (cytoskeleton) to proteins in cell membranes. Several different mutations of the NF2 gene have been identified in individuals with the disorder (e.g., deletions, nonsense and frameshift mutations).

 

Neurofibromatosis 2 Treatment

The treatment of vestibular (acoustic) neuromas associated with NF2 is the surgical removal of the tumors, when possible. The surgical procedure that is performed is based upon the size and precise location of the tumors. Radiation therapy may be considered for some individuals with this disorder, especially those who are not candidates for surgery. The VEGF inhibitor bevacizumab may also be considered to treat rapidly growing schwannomas but is very expensive.

 

Neurofibromatosis 2 Key Players

  • AstraZeneca
  • Recursion Pharmaceuticals

 

Neurofibromatosis 2 Emerging Drugs

  • Selumetinib
  • REC-2282

 

Neurofibromatosis 2 Pipeline Development Activities

The report provides insights into:

 

  • All of the companies that are developing therapies for the treatment of Neurofibromatosis 2 with aggregate therapies developed by each company for the same.
  • Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Neurofibromatosis 2 treatment.
  • Neurofibromatosis 2 key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Neurofibromatosis 2 market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc. 

 

Neurofibromatosis 2: Report Highlights

  • A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Neurofibromatosis 2.   
  • In the coming years, the Neurofibromatosis 2 market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies and academics that are working to assess challenges and seek opportunities that could influence Neurofibromatosis 2 R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • A detailed portfolio of major pharma players who are involved in fueling the Neurofibromatosis 2 treatment market. Several potential therapies for Neurofibromatosis 2 are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Neurofibromatosis 2 market size in the coming years. 
  • Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Neurofibromatosis 2) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

 

Download free sample copy of Neurofibromatosis 2 pipeline report- https://www.delveinsight.com/sample-request/neurofibromatosis-2-pipeline-insight

 

Following is the table of content of Neurofibromatosis 2 pipeline report

1. Report Introduction

2. Neurofibromatosis 2 

3. Neurofibromatosis 2 Current Treatment Patterns

4. Neurofibromatosis 2 – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Neurofibromatosis 2 Late Stage Products (Phase-III)

7. Neurofibromatosis 2 Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Neurofibromatosis 2 Discontinued Products

13. Neurofibromatosis 2 Product Profiles

14. Neurofibromatosis 2 Key Companies

15. Neurofibromatosis 2 Key Products

16. Dormant and Discontinued Products

17. Neurofibromatosis 2 Unmet Needs

18. Neurofibromatosis 2 Future Perspectives

19. Neurofibromatosis 2 Analyst Review  

20. Appendix

21. Report Methodology

 

Neurofibromatosis 2: Key Questions

  • What are the current options for Neurofibromatosis 2 treatment?
  • How many companies are developing therapies for the treatment of Neurofibromatosis 2?
  • What are the principal therapies developed by these companies in the industry?
  • How many therapies are developed by each company for the treatment of Neurofibromatosis 2?
  • How many Neurofibromatosis 2 emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Neurofibromatosis 2?
  • Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Neurofibromatosis 2 market?
  • Which are the dormant and discontinued products and the reasons for the same?
  • What is the unmet need for current therapies for the treatment of Neurofibromatosis 2? 
  • What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Neurofibromatosis 2 therapies?
  • What are the clinical studies going on for Neurofibromatosis 2 and their status?
  • What are the results of the clinical studies and their safety and efficacy?
  • What are the key designations that have been granted for the emerging therapies for Neurofibromatosis 2?
  • How many patents are granted and pending for the emerging therapies for the treatment of Neurofibromatosis 2?

 

Related Reports 

 

 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles